Join the thousands of HNF volunteers who are fueling CMT research. The more you share, the more we’ll learn. Complete your GRIN surveys today!



"ABCs of CMT Pain Management" is now on Amazon! The Hereditary Neuropathy Foundation is thrilled...
a patient-initiated at-home genetic testing program, providing faster and more equitable access to critical genetic care for the CMT community and their health care providers.
ABCs of CMT Pain Management,” a comprehensive guide that is a direct product of the Global Registry for Inherited Neuropathies (GRIN) initiative.
In July 2023, Novartis announced the acquisition of DTx Pharma, a San-Diego based, preclinical stage biotechnology company focused on leveraging its proprietary FALCON platform to develop siRNA therapies for neuroscience indications.
Congratulations to GRIN Advisory Board member, Professor Joshua Burns, for being recognized by the Australian Academy of Health and Medical Sciences for his outstanding contributions to medical and health sciences.
Meet virtually with host, Julie Stone & fellow CMTers from all over the world for a fun and...
Pediatric CMT Natural History Study enhancement to their Charcot-Marie-Tooth (CMT) and Inherited Neuropathies (IN) patient registry, Global Registry for Inherited Neuropathies (GRIN).
The Hereditary Neuropathy Foundation (HNF), an advocacy and research 501c3 non-profit, today...
Dtx today announced that the FDA has granted Orphan Drug Designation to DTx-1252, an investigational FALCON small interfering RNA (siRNA) therapeutic for the treatment of Charcot-Marie-Tooth Disease Type 1A (CMT1A).
Pharnext announces new positive results from the ongoing open-label extension study of their drug PXT3003
0 Comments